Journal
MOLECULES
Volume 26, Issue 3, Pages -Publisher
MDPI
DOI: 10.3390/molecules26030604
Keywords
embryonic stem cells; mesenchymal stem cells; osteoarthritis; cell therapy; tissue repair
Funding
- National Natural Science Foundation of China [81973606]
- Peking University People's Hospital Scientific Research Development Funds [RDY2019-11]
- Beijing Science and Technology Major Projects [Z181100001818008]
- International Partnership Program of Chinese Academy of Sciences [152111KYSB20160004]
- National Health and Medical Research Council (Australia) [GNT1120249]
- international cooperation project of China Manned Space Program
Ask authors/readers for more resources
The study demonstrates that multiple injections of ES-MSCs can improve osteoarthritis in a rat model. The repeated doses group showed more proteoglycan and less cartilage loss, along with lower Mankin scores, indicating the potential of ES-MSCs as a regenerative therapy for OA.
Mesenchymalstem cell (MSC)-based therapy is being increasingly explored in preclinical and clinical studies as a regenerative method for treating osteoarthritis (OA). However, the use of primary MSCs is hampered by a number of limitations, including donor heterogeneity and inconsistent cell quality. Here, we tested the therapeutic potential of embryonic stem cell-derived MSCs (ES-MSCs) in anOA rat model. ES-MSCs were generated and identified by morphology, trilineage differentiation and flow cytometry. Sprague Dawley rats were treated with either a single dose (10(6) cells/rat) of ES-MSCs or with three doses spaced one week apart for each dose, starting at four weeks after anterior cruciate ligament transectionto induce OA. Cartilage quality was evaluated at 6 and 10 weeks after treatment with behavioral analysis, macroscopic examination, and histology. At sixweeks after treatment, the groups treated with both single and repeated doses of ES-MSCs had significantly better modified Mankin scores and International Cartilage Repair Society (ICRS) macroscopic scores in the femoral condyle compared to the control group. At 10 weeks after treatment, the repeated doses group had a significantly better ICRS macroscopic scores in the femoral condyle compared to the single dose and control groups. Histological analysis also showed more proteoglycan and less cartilage loss, along with lower Mankin scores in the repeated doses group. In conclusion, treatment with multiple injections of ES-MSCs can ameliorate OA in a rat model. TheES-MSCs have potential to be considered as a regenerative therapy for OA, and can provide an infinite cellular source.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available